SARS-CoV-2 Seroprevalence Across a Diverse Cohort of Healthcare Workers
Authors:
- Joseph E. EbingerJEJoseph E. Ebinger
- Gregory J. BotwinGBGregory J. Botwin
- Christine M. AlbertCAChristine M. Albert
- Mona AlotaibiMAMona Alotaibi
- Moshe ArditiMAMoshe Arditi
- Anders H. BergABAnders H. Berg
- Aleksandra BinekABAleksandra Binek
- Patrick G. BottingPBPatrick G. Botting
- Justyna Fert-BoberJFJustyna Fert-Bober
- Jane C. FigueiredoJFJane C. Figueiredo
- Jonathan D. GreinJGJonathan D. Grein
- Wohaib HasanWHWohaib Hasan
Preprint
Abstract
Importance: Antibody testing is important for understanding patterns of exposure and potential immunity to SARS-CoV-2. Prior data on seroprevalence have been subject to variations in selection of individuals and nature as well as timing of testing in relation to exposures. Objective: We sought to determine the extent of SARS-CoV-2 seroprevalance and the factors associated with seroprevelance across a diverse cohort of healthcare workers. Design: Observational cohort study of healthcare workers, including SARS-CoV-2 serology testing and participant questionaires. Participants: A diverse and unselected population of adults (n=6,062) employed in a multi-site healthcare delivery system located in Los Angeles County, including individuals with direct patient contact and others with non-patient-oriented work functions. Exposure: Exposure and infection with the SARS-CoV-2 virus, as determined by seropositivity. Main Outcomes: Using Bayesian and multi-variate analyses, we estimated seroprevalence and factors associated with seropositivity and antibody titers, including pre-existing demographic and clinical characteristics; potential Covid-19 illness related exposures; and, symptoms consistent with Covid-19 infection. Results: We observed a seroprevalence rate of 4.1%, with anosmia as the most prominently associated self-reported symptom in addition to fever, dry cough, anorexia, and myalgias. After adjusting for potential confounders, pre-existing medical conditions were not associated with antibody positivity. However, seroprevalence was associated with younger age, Hispanic ethnicity, and African-American race, as well as presence of either a personal or household member having a prior diagnosis of Covid-19. Importantly, African American race and Hispanic ethnicity were associated with antibody positivity even after adjusting for personal Covid-19 diagnosis status, suggesting the contribution of unmeasured structural or societally factors. Notably, number of people, or children, in the home was not associated with antibody positivity. Conclusion and Relevance: The demographic factors associated with SARS-CoV-2 seroprevalence among our healthcare workers underscore the importance of exposure sources beyond the workplace. The size and diversity of our study population, combined with robust survey and modeling techniques, provide a vibrant picture of the demographic factors, exposures, and symptoms that can identify individuals with susceptibility as well as potential to mount an immune response to Covid-19. Key Points: Question: What is the SARS-CoV-2 IgG seroprevalence rate across a large and diverse healthcare worker population, and which clinical, envionrmental, and symptom-based measures are associated with seropositivity? Findings: We observed a seroprevalence rate of 4.1%. Adjusting for potential confounders, seropositivity was associated with younger age, Hispanic ethnicity, African-American race, and the symptom of anosmia, while not significantly associated with any pre-existing medical conditions. Meaning: Factors associated with SARS-CoV-2 seroprevalence among our healthcare workers underscore the importance of exposure sources beyond the workplace.Keywords
All Related Versions
- Published version: BMJ Open, 11 (2), e043584.
This publication has 41 references indexed in Scilit:
- An Opportune and Relevant Design for Studying the Health Trajectories of Healthcare WorkersmedRxiv, 2020
- Review of Current Advances in Serologic Testing for COVID-19American Journal of Clinical Pathology, 2020
- The prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in intensive care unit (ICU) healthcare personnel (HCP) and its implications—a single-center, prospective, pilot studyInfection Control & Hospital Epidemiology, 2020
- SARS-CoV-2 infection serology: a useful tool to overcome lockdown?Cell Death Discovery, 2020
- Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forwardScience Immunology, 2020
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in IdahomedRxiv, 2020
- Will antibody tests for the coronavirus really change everything?Nature, 2020
- Developing antibody tests for SARS-CoV-2The Lancet, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009